November 12, 2020 – The Temple University Health System recently expanded its point-of-care eye screening program to twelve general practice and internal medicine clinics throughout the city of Philadelphia. In each of these locations, frontline healthcare professionals will utilize Eyenuk’s FDA-cleared EyeArt® autonomous AI technology for point-of-care detection of more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR). Eyenuk’s EyeScreenTM Human+AI Eye Screening System will provide additional telemedicine assistance to the Temple University Department of Ophthalmology for further disease evaluation.
In a recent educational webinar titled “Diabetic Eye Screening for the Masses: Are We Ready for Autonomous AI?”, Professor Jeffrey R. Henderer, MD, Chair of Ophthalmology at Temple University Lewis Katz School of Medicine, shared Temple University’s tele-ophthalmology vision and the important role of Eyenuk’s AI technologies. He emphasized that a successful large-scale eye screening program should be effective and efficient, but traditional eye screening programs suffered from multiple implementation barriers, such as poor image quality, inconsistent and delayed image interpretation, as well as challenges with patient scheduling and follow-up.
How does the EyeArt system help address these issues? “By providing an immediate interpretation, EyeArt will indicate if the photo was of sufficient quality. That will let the photographer know that another photo is needed and should cut down on the number of uninterpretable photos. EyeArt also eliminates the problem of non-standard photo interpretation. We hope that by providing immediate feedback to the patient and the PCP, we will be able to improve the follow up scheduling rates, and we hope that a shorter appointment lag time will improve the patient show rate.,” said Professor Henderer.
Click here to view the full webinar on-demand and learn more about the scientific proof and practical applications of Eyenuk’s AI technologies.